Close

BTIG Starts Ironwood Pharmaceuticals (IRWD) at Buy

December 11, 2015 8:39 AM EST
Get Alerts IRWD Hot Sheet
Price: $8.71 +1.04%

Rating Summary:
    14 Buy, 11 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE

BTIG initiated coverage on Ironwood Pharmaceuticals (NASDAQ: IRWD) with a Buy rating and a price target of $15. Analyst Timothy Chiang noted that Linzess was steadily ramping and Viberzi was launching.

Chiang said, "We believe IRWD shares are attractive based on improving visibility with its GI-focused pipeline ... With 2015-18 revenues forecasted at $140 million, $225 million, $303 million, and $385 million, respectively, we estimate IRWD to reach profitability in 2017, with forecasted EPS of $1.06 in 2019.

For an analyst ratings summary and ratings history on Ironwood Pharmaceuticals click here. For more ratings news on Ironwood Pharmaceuticals click here.

Shares of Ironwood Pharmaceuticals closed at $11.30 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS View, New Coverage